BriaCell Therapeutics Corp.

BCT.TOTSXHealthcare● Active

$4.35

+$0.04(+0.93%)

Market Cap$8194273

P/E Ratio—

52W High$49

52W Low$4.13

Avg Volume15K

Open$4.31

Beta1.64

Free Cash Flow Financials Revenue

BriaCell Therapeutics Corp. (BCT.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BCT.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

BCT.TO · FCF · TTM · margin & CAGR

Free cash flow was −$28.5M for FY2025 (fiscal year ending 2025-07-31), down 16.0% year-over-year

FY2025 Free Cash Flow−$28.5M▼ -16.0% YoY

Trailing 12M (TTM)−$31.0Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BCT.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$28.5M(0M)−$28.5M▼ 16.0%—

FY2024−$24.1M(0M)−$24.6M▼ 3.5%—

FY2023−$23.7M(0M)−$23.7M▼ 90.2%—

FY2022−$12.5M(0M)−$12.5M▼ 61.1%—

FY2021−$7.8M(0M)−$7.8M▼ 398.7%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BCT.TO · P/FCF · FCF yield · FCF per share

BriaCell Therapeutics Corp. (BCT.TO) reported negative free cash flow of −$0.03B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-07-31

Cash flow statement summary

BCT.TO · cash flow statement · operating / investing / financing

For FY2025, BriaCell Therapeutics Corp. generated −$28.5M in operating cash flow and spent 0M in capital expenditures, yielding −$28.5M in free cash flow.

Operating Activities

−$28.5M

Cash from core business operations

2025-07-31

Investing Activities

−$7.7M

CapEx, acquisitions & investments

2025-07-31

Financing Activities

+$46.0M

Buybacks, dividends & debt

2025-07-31

FCF FormulaOperating CF (−$28.5M) − |CapEx| (0M) = FCF (−$28.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BCT.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BriaCell Therapeutics Corp.YOU

BCT.TO

−$28.5M-16.0%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BriaCell Therapeutics Corp. (BCT.TO) reported free cash flow of −$28.5M for FY2025 (fiscal year ending 2025-07-31), down 16.0% year-over-year.

BriaCell Therapeutics Corp. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BCT.TO free cash flow · 8 questions

BriaCell Therapeutics Corp. free cash flow was −$28.5M for FY2025, down 16.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$31.0M.

BCT.TO free cash flowBCT.TO FCFBCT.TO FCF 2025BCT.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BriaCell Therapeutics Corp. · BriaCell Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026